{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:01:57Z","timestamp":1787504517641,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.amjcard.2024.08.029","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T20:05:15Z","timestamp":1725307515000},"page":"20-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Management of Cancer Therapy\u2013Related Cardiac Dysfunction: A Case-Based Review"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3247-4932","authenticated-orcid":false,"given":"Jaya","family":"Mallidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Baylis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.08.029_bib0001","unstructured":"American Cancer Society. Cancer treatment & survivorship facts & figures 2022\u20132024. Available at: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/survivor-facts-figures.html. Accessed on August 21, 2024."},{"key":"10.1016\/j.amjcard.2024.08.029_bib0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12609-017-0249-4","article-title":"Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer","volume":"9","author":"Nowsheen","year":"2017","journal-title":"Curr Breast Cancer Rep"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Italian Cardio-Oncologic Network. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0004","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0005","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0007","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J Mol Cell Cardiol"},{"issue":"suppl 10","key":"10.1016\/j.amjcard.2024.08.029_bib0008","first-page":"72","article-title":"Epidemiology of anthracycline cardiotoxicity in children and adults","volume":"25","author":"Grenier","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0009","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0011","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0012","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II\u03b2\u2013mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.bjc.6601904","article-title":"Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy","volume":"91","author":"Pein","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021931","article-title":"Development and validation of a risk score model for predicting the cardiovascular outcomes after breast cancer therapy: the CHEMO-RADIAT score","volume":"10","author":"Kim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0015","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0016","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1007\/s12350-018-1293-9","article-title":"Cardiac MRI for the evaluation of oncologic cardiotoxicity","volume":"25","author":"L\u00f6ffler","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0018","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0019","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0021","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2024.08.029_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0023","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.toxlet.2018.01.001","article-title":"Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes","volume":"285","author":"Kurokawa","year":"2018","journal-title":"Toxicol Lett"},{"issue":"8","key":"10.1016\/j.amjcard.2024.08.029_bib0024","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/OP.23.00816","article-title":"Trastuzumab-induced cardiotoxicity: When and how much should we worry?","volume":"20","author":"Zheng","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"10.1016\/j.amjcard.2024.08.029_bib0025","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): A randomized trial for the prevention of Trastuzumab-Associated Cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0027","first-page":"472","article-title":"Immune checkpoint inhibitor associated myocarditis and cardiomyopathy: a translational review","volume":"12","author":"Wang","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0028","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0029","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0031","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0032","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0033","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaccao.2019.09.007","article-title":"Cancer therapy-related cardiac dysfunction of nonanthracycline chemotherapeutics: what is the evidence?","volume":"1","author":"Kamphuis","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0036","doi-asserted-by":"crossref","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0037","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1008309916974","article-title":"Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin","volume":"10","author":"Colombo","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0038","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0039","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0041","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13273-018-0027-z","article-title":"Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy","volume":"14","author":"Lee","year":"2018","journal-title":"Mol Cell Toxicol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0042","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy\u2013associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0043","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy\u2013related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0044","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0045","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/eurheartj\/eht114","article-title":"Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease","volume":"35","author":"Groarke","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0046","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2017.77.6351","article-title":"Cardiac structure injury after radiotherapy for breast cancer: cross-sectional study with individual patient data","volume":"36","author":"Taylor","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2024.08.029_bib0047","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924006337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924006337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:33:11Z","timestamp":1730295191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924006337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":47,"alternative-id":["S0002914924006337"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.08.029","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Cancer Therapy\u2013Related Cardiac Dysfunction: A Case-Based Review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}